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ABSTRACT
As we move toward an era of precision medicine,
novel biomarkers of disease will enable the
identification and personalized treatment of
new endotypes. In asthma, fractional exhaled
nitric oxide (FeNO) serves as a surrogatemarker of
airway inflammation that often correlates with
the presence of sputum eosinophils. The increase
in FeNO is driven by an upregulation of inducible
nitric oxide synthase (iNOS) by cytokines, which
are released as a result of type-2 airway
inflammation. Scientific evidence supports using
FeNO in routine clinical practice. In steroid-naive
patients and in patients with mild asthma, FeNO
levels decrease within days after corticosteroid
treatment in a dose-dependent fashion and
increase after steroid withdrawal. In difficult
asthma, FeNO testing correlates with
anti-inflammatory therapy compliance.
Assessing adherence by FeNO testing can
remove the confrontational aspect of
questioning a patient about compliance and
change the conversation to one of goal setting
and ways to improve disease management.
However, the most important aspect of
incorporating FeNO in asthma management is
the reduction in the risk of exacerbations. In a
recent primary care study, reduction of
exacerbation rates and improved symptom
control without increasing overall inhaled
corticosteroid (ICS) use were demonstrated
when a FeNO-guided anti-inflammatory
treatment algorithm was assessed and compared
to the standard care. A truly personalized asthma
management approach—showing reduction of
exacerbation rates, overall useof ICSandneonatal
hospitalizations—was demonstrated when FeNO
testing was applied as part of the treatment
algorithm that managed asthma during
pregnancy. The aim of this article is to describe
how FeNO and the NIOX VERO analyzer can
help to optimize diagnosis and treatment choices
and to aid in themonitoring and improvement of
clinical asthma outcomes in children and adults.
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AND THE BEGINNING OF THE AGE
OF PRECISION MEDICINE
Fifteen years ago, I was interviewed for a
research fellowship. I think the two eminent
professors leading the questioning were quietly
enjoying themselves. Indeed, I was finding the
experience quite jolly until I was asked a simple
but insightful question. One of my interviewers
(a respiratory pediatrician and superb
researcher) looked me in the eye and asked,
‘Are you a lumper or a splitter?’ I fumbled for a
few poorly chosen words and played for time by
suggesting that it depended upon the context,
but I did not give a particularly illuminating
answer. I cannot honestly recall whether I
finally decided whether I was, at heart, a
lumper or a splitter. I did, however, get the job.
In the intervening years, I have considered
this question deeply. Lumping has distinct
advantages; in clinical settings, it allows
guidelines to be constructed and applied. By
‘lumping’ a group of heterogeneous wheezing
disorders of childhood together and applying a
diagnostic label of ‘asthma,’ we have created a
condition that is sufficiently common and
important to enable research and develop an
evidence base for treatment. Moreover, the
simplistic approach of combining distinct
phenotypes under a single term enables
educational strategies to be adopted on a large
scale. However, despite a wealth of evidence
and the production of high-quality national
and international guidelines, asthma control
remains poor for most children. The gap
between optimal outcomes for children with
asthma in research settings and observed
outcomes is undoubtedly multifactorial.
However, the current strategy of lumping is
not serving children with asthma or their
families.
Guidelines currently suggest, for the most
part, a ‘one size fits all’ approach with a
step-up and step-down scheme that belies the
inherent complexity and variation seen
between individuals. Precision medicine is a
new term that describes an approach for
disease treatment and prevention that takes
into account individual variability in genes,
environment, and life choices. It facilitates
the customization of health care tailored to
each individual patient. It is particularly
valuable for conditions such as asthma
where there is considerable heterogeneity in
phenotype. While precision medicine is
evolving, and has had notable successes in
the treatment of some types of cancer, it is
not currently in use for most diseases, and
asthma is no exception.
There are ranges of clinical and genetic
factors, which are known to have some value
in predicting the response to treatment in
children with asthma. Thus, age, atopic status,
bronchodilator responsiveness (BDR), ethnicity,
gender, ethnicity and obesity have all been
shown to predict responsiveness to inhaled
corticosteroids (ICSs), leukotriene receptor
antagonists (LTRA) and long-acting beta-2
agonists in selected populations of children
(Table 1) [1–4].
These observations may be helpful in
choosing ‘what next?’ when children present
with persistent symptoms or recurrent
exacerbations. However, these factors are often
superseded by practical considerations in
clinical practice. For instance, a young child
who is uncooperative with the administration
of inhaled medicines will be less likely to benefit
from an inhaled treatment, and oral therapy
may be more successful.
Biomarkers are likely to play an important
role in the application of precision medicine to
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clinical practice. They have an established role
in improving diagnosis and can accurately
predict treatment response. A role probably
exists for a range of markers including sputum
eosinophils, exhaled breath condensate and the
pattern of volatile organic compounds (VOCs).
This article critically reviews the role of
fractional exhaled nitric oxide (FeNO) and
specifically the role of the NIOX VERO in the
application of precision medicine to children
and adults with asthma.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by the
author. It is a commissioned, peer-reviewed
article specifically aimed at giving details of
asthma endotypes and the use of the NIOX
VERO device in clinical practice.
ENDOTYPES: EXHALED NITRIC
OXIDE AND HOW IT RELATES
TO ASTHMA
Initial attempts at subdividing asthma types
were dependent upon careful delineation of the
observable characteristics and clinical features,
the phenotype. Originally, this led to a division
between intrinsic and extrinsic asthma. In the
last decade, there has been a renewed
enthusiasm within the research community to
split, or subdivide, the asthma phenotype [5].
This renewed interest has, to an extent, been
the result of increased availability of
mathematical modelling to approach the
available patient data [6]. This has resulted in
a ‘re-discovery’ of work initially conducted in
Derby in the late 1950s that identified the
importance of sputum eosinophilia in
determining treatment response [7, 8].
Phenotypical analysis is fraught with
difficulty. Most biological characteristics or
laboratory indices are not dichotomous but
continuous; moreover, they are variable over
time and influenced by treatment. In an
attempt to resolve these difficulties, there has
been a shift away from phenotyping to
endotyping [9]. An endotype is defined by a
distinct functional or pathobiological
mechanism. This has led to the identification
of new distinct groups of children and adults
with asthma. Some examples of how
phenotypes may overlap with multiple
endotypes in children and adults are given in
Table 2.
The relationship between exhaled nitric
oxide (eNO) and asthma is complex. Nitric
oxide is produced by nitric oxide synthase
(NOS) enzymes and is extremely short lived
unlike other biological markers. There are
three distinct forms of NOS enzymes:
endothelial (eNOS), inducible (iNOS) and
neuronal (nNOS). eNO is produced in the
lung epithelia as a result of expression of
iNOS [10, 11]. The activity of iNOS is highly
variable, and the concentration of eNO on
the breath is dependent upon many factors
including the degree of type-2 airway
Table 1 Factors reported to predict differential response
to inhaled corticosteroids and leukotriene receptor
antagonists
Favors LTRA Favors ICS
Young age [3] Poor lung function [3]






ICS inhaled corticosteroids, FeNO fractional exhaled nitric
oxide, LTRA leukotriene receptor antagonists
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inflammation, presence of other atopic
diseases, exposure to environmental tobacco
smoke and body mass index (Table 3)
[12–20].
Despite this apparent heterogeneity, eNO
has established itself within clinical guidelines
as a useful adjunct in the diagnosis of asthma in
children and adults [21]. Moreover, changes
over time within an individual can be extremely
helpful in determining response to treatment
profiles and indirectly confirming adherence
patterns [22].
While eNO concentrations provide evidence
of type-2 airway inflammation, FeNO
measurement is relatively cheap to perform, is
noninvasive and is performed easily in children
above 4 years of age. A number of commercially
available systems measuring FeNO are available
to clinicians, and I have previously written
about my experience with one of these (NIOX
MINO) [22].
NIOX VERO: THE LATEST
GENERATION DEVICE TO MEASURE
FENO
There are many devices available commercially
for the measurement of FeNO in clinical
practice. NIOX VERO (Fig. 1a) is a
point-of-care, hand-held, electrochemical
FeNO analyzer and is the next-generation
device from the predicate, NIOX MINO
(Fig. 1b). NIOX VERO complies with all
essential aspects of the American Thoracic
Society (ATS) and European Respiratory Society
(ERS) recommendations for standardized
exhaled NO measurement procedures [23] and
has been recently cleared for use in the US,
Japan and China. In order to complete this
review article, I contacted the manufacturer of
the NIOX VERO device to determine what
validation had been undertaken prior to its
release. These data were provided upon request
Table 2 Asthma endotypes and their proposed relationship to phenotypes
Phenotype Possible endotypes
Children
Eosinophilic asthma Allergic asthma, e.g., atopic child with inhaled steroid responsive disease
Exacerbation-prone
asthma
Preschool episodic viral induced wheezer, multiple trigger wheezer
Exercise-induced asthma Preschool multiple trigger wheezer (exercise-triggered)
Poorly steroid-responsive
asthma
Obesity associated asthma; neutrophilic asthma; steroid-insensitive eosinophilic asthma
Adults




Allergic asthma; aspirin-sensitive asthma; late-onset hypereosinophilic asthma; ABPA,
catamenial asthma
Exercise-induced asthma Cross-country skiers’ asthma, elite-athlete asthma
Poorly steroid-responsive
asthma
Chronic obstructive pulmonary disease overlap; obesity associated asthma; neutrophilic
asthma; steroid-insensitive eosinophilic asthma
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by Cirassia/Aerocrine. To date, two technical
validation studies and two clinical validation
studies have been performed by the
manufacturer that have supported the clinical
utility of NIOX VERO, the results of which are
summarized in the following sections.
DATA SUPPORTING PRECISION
AND ACCURACY
To calculate the precision and accuracy,
mixtures of a certified calibration gas of
200 ppb NO in nitrogen were used, yielding
concentrations of 5, 25, 75 and 200 ppb. The
gas mixer was connected in line with the NIOX
VERO instrument, and five sensors were
mounted in five NIOX VERO instruments.
Precision
This was determined in house by the
manufacturer. Two replicate determinations of
each concentration were made twice a day
(more than 2 h apart) for 20 days. The
repeatability and within-device precision were
calculated for five instruments. Both standard
deviation (SD) estimates met the precision
claim at all four concentration levels, and the
repeatability and within-device precision were
well within the specification limit: \3 ppb of
measured values \30 ppb and \10 % of
measured values [30 ppb. Both SD estimates
for repeatability and within-device precision
met the precision claim in the labeling at all
four concentration levels.
Accuracy
This is the deviation of the measured value from
a known nominal value, i.e., the certified
concentration of a NO reference standard. Two
replicate determinations were made at each
occasion. For each test occasion the mean NO
concentration (M) for each set of replicates and
Table 3 Factors known to be associated with fractional
exhaled nitric oxide concentrations in children and adults
with asthma
Increased FeNO Decreased FeNO
Airway eosinophilia [13] Environmental tobacco
smoke exposure [14]
Total IgE [15–17] Neonatal respiratory
distress syndrome [16]
Ingestion of nitrate rich





FeNO fractional exhaled nitric oxide, IgE immunoglobulin E
Fig. 1 a The NIOX VERO portable exhaled nitric oxide
analyzer. b The NIOX MINO portable exhaled nitric
oxide analyzer
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the absolute deviation of each replicate mean
(D) from the nominal gas concentration
(G) were calculated. The mean D, SD and 95 %
confidence interval (CI) for all instruments were
calculated. At[50 ppb concentration levels, D is
expressed as a percentage of the nominal NO
concentration. The results for the five NIOX
VERO systems showed the accuracy was within
the technical specification: ±5 ppb\50 ppb or
maximum 10 % at[50 ppb.
DATA-SUPPORTING AGREEMENT
AND REPEATABILITY
NIOX VERO Versus NIOX MINO: Are
the Results Obtained Comparable
in Clinical Practice?
Pooled data from two randomized,
multi-center, single-visit studies in 112 subjects
aged C7 years demonstrated clinically
acceptable agreement between the NIOX
VERO and NIOX MINO devices and
supported a high degree of intra-subject
repeatability with the new device. The mean
observed paired difference for the first valid
FeNO measurement on each device was
-4.6 ppb (95 % CI -5.825 to -3.377;
p\0.0001). Weighted Deming regression
analysis showed paired differences were
centered close to 0. Agreement was also seen
when comparing the first valid FeNO
measurement or the mean of
two measurements. Intra-subject repeatability
of NIOX VERO was significantly better than
for NIOX MINO (p = 0.0112). Although FeNO
measurements using the NIOX VERO were
slightly lower than with the NIOX MINO,
there were no substantial differences between
replicates within age groups, gender groups or
randomization sequences, and the difference
was within the technical specifications of the
device (Fig. 2).
Inter-Operator Repeatability
Pooled data from two multi-center, single-visit,
point-of-care studies showed that NIOX VERO
Fig. 2 Agreement and repeatability data for NIOX VERO
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gave repeatable and consistent FeNO
measurements with no observable pattern of
training effect or order effect on FeNO
when measured three times by three different
operators. The studies were performed in
122 subjects aged C7 years with
physician-diagnosed asthma; the majority had
mean FeNO values of\50 ppb with a mean of
31.4 ± 32.97 ppb overall and ranged from 5 to
174 ppb. Intra-subject mean FeNO values were
not significantly different for subjects with
FeNO \50 ppb versus those with C50 ppb
(p = 0.9979 versus p = 0.8006). A total of 54
operators participated, of which 46 % were
registered nurses and 20 % were licensed
practical nurses or had an associated nursing
degree. Inter-operator repeatability was
demonstrated with a mean intra-subject
variance of 6.61 ± 17.954 ppb (upper 95 % CI
9.41). The coefficient of variance was
0.066 ± 0.054 (upper 95 % CI 0.074) (Fig. 3).
Weighted Deming regression analysis of the
three possible pairs of measurements showed no
evidence of bias relating to the order of testing
with an estimated bias of \2 % for all pairs;
these findings provided further evidence of
repeatability. Repeatability was also shown for
those subjects with a mean FeNO\50 ppb, the
within-subject paired FeNO difference was
\10 ppb, and the majority of subjects (97 %)
with a mean FeNO C50 ppb had a difference
B20 %. Hence, while the variability in
intra-subject FeNO values increased with
higher values, the CVs (upper 95 % CI) from
both subject groups remained similar [0.072
(0.082) versus 0.048 (0.060)].
Fig. 3 Individual fractional exhaled nitric oxide measure-
ments versus subject mean fractional exhaled nitric oxide
measurements for pooled study data efﬁcacy subjects
Note: Subjects with a FeNOmeasurement recorded as\5 ppb
were considered to have a FeNO measurement = 5 ppb.
Note: Dashed lines represent lines of slope = 1.2 and 0.8.
fenores.ﬁg generated by fenores.sas on 11AUG14: 11:36
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Ease of Use
The NIOX VERO device provides a slightly
different user experience with some advantages
over the NIOX MINO device. My personal
observation in clinical practice with children
and adolescents is that the ‘in-built’ nature of
the incentive software is advantageous and
reduces the overall ‘set-up’ time required to
obtain a single measurement. In most other
respects, the user experience and feedback are
equivalent, and even young children (4 years
and older) are able to perform measurements
using the 6-s mode (see below) after relatively
little coaching.
A user-device interaction two-center study
was conducted in eight female users who
reported Swedish as their primary language and
held education in healthcare; none had previous
experience with the NIOX VERO device, but
seven of eight were familiar with NIOX MINO.
All users could operate the device and assess
user-device instructions with the NIOX Panel.
The majority of tasks were completed without
assistance (75 %); one user required help to
create a quality control (QC) user and perform a
QC test, and two users needed assistance to
handle the exemption at foreseeable misuses and
stop exhaling before the analysis time was
finished; the observer indicated that only one
user actually needed help. Where one was worst
imaginable and five were best imaginable, the
overall impression was rated between 3 and 4,
while ease-of-use and visual impression were
rated between 4 and 5.
Are There Improvements over NIOX
MINO?
As already shown, intra-subject repeatability of
the NIOX VERO is significantly better than for
NIOX MINO. Moreover, NIOX VERO can be
used without connection to a power supply and
better visibility of the display screen, enabling a
degree of portability and flexibility in the
clinical setting. Experienced users of the NIOX
MINO will undoubtedly recall the frustration
of an accidental power cable disconnection
(usually by the child) after a successful
exhalation prior to the calculation of the eNO
value. As with NIOX MINO, the NIOX VERO
can be operated using the 10- and 6-s
exhalation modes in a clinical setting and in
young children aged 4 years and older. The 6-s
mode is particularly useful in clinical practice
with younger children.
A randomized, single-visit, clinical
validation study was conducted using NIOX
VERO in asthmatic children aged 4–10 years.
Data from the subgroup aged 6–10 years (mean
age 8.1 years) showed a high level of agreement
between the 6- and 10-s modes, and this was
further demonstrated using a Weighted Deming
regression analysis in which the intercept
was 0 and slope was 1.0. Furthermore, FeNO
measurements were repeatable with a median
intra-subject SD of 0.707 for both modes and no
significant differences (p = 0.3090). Children in
the subgroup aged 4–5 years also successfully
used the NIOX VERO using the 6- and 10-s
modes, with greater success seen using the
former. Mean FeNO results were comparable
between the 6-s (12.6 ppb) and 10-s (10.6 ppb)
modes (Table 4).
DATA TO SUPPORT MEASURING
FENO IN CLINICAL PRACTICE
FeNO provides a complementary and
noninvasive assessment of airway
inflammation when used alongside more
traditional methods, such as history,
examination, spirometry and bronchial lability
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measures [24–26]. It provides a more complete
assessment of asthma severity and control
[27, 28] than traditional assessments, has
utility in primary care settings and can be
measured in patients of most ages.
Furthermore, FeNO is useful for monitoring
adherence to anti-inflammatory medications
and predicting exacerbation risk [27, 29] and
offers potential cost savings [26, 30, 31].
Diagnosis
In primary care clinical practice, the monitoring
of asthma control is currently focused on
evaluating clinical symptoms and lung
function parameters. However, GINA
guidelines and ATS FeNO guidelines suggest
that airway inflammation could be assessed to
optimize treatment strategies [11, 32, 33].
FeNO is used to define and confirm airway
allergic and eosinophilic inflammation in
patients with asthma [16]. Routine use of
FeNO alongside traditional clinical assessments
may improve diagnostic accuracy and enables
tailored therapeutic regimens [16, 34, 35]. In a
study comparing FeNO and sputum cell counts
with serial spirometry and peak flow recordings
in children and adults, the sensitivity of
spirometry was lower (47 %) than that of
either FeNO (88 %) or sputum induction
(86 %) [32, 36]. In addition, FeNO and sputum
eosinophils showed a specificity of 92 %
compared with 73 % for spirometry [32, 36].
Given that FeNO is representative of
Th2-driven local inflammation specifically in
the bronchial mucosa [32, 37–39], it has the
potential to predict the response to ICS therapy
in asthma [3, 40–46]. Data suggest that asthma
patients who have elevated baseline FeNO levels
are more likely to respond to ICS than those
with baseline FeNO levels within predefined
normal ranges [32, 40, 41, 47]. However, there is
conflicting evidence: in a study by Klaassen
et al., symptoms not FeNO levels predicted
response to ICS [48], and Prieto et al. showed
that FeNO was not useful in predicting response
above a baseline cut-off of 20 ppb [49].
However, in the first study, FeNO was
measured using an offline tidal breathing
method rather than the recommended online
measurement [48].
FeNO is of particular interest for diagnosing
and phenotyping asthma in children with
suspected asthma, therefore enabling optimal
treatment and control (Fig. 4; Table 5).
Diagnosing asthma in children, particularly
pre-schoolers, can be challenging. The
advantage of FeNO is that, unlike other
assessments, it does not involve a forced vital
capacity maneuver, which makes it easier for
children, and especially young children, to
perform, therefore aiding cooperation [50].
Furthermore, the measurements are easy,
quick to perform in the clinic and
Table 4 Fractional exhaled nitric oxide results for subjects
aged 4–5 years by exhalation time mode
Number of subjects 12
FeNO 6 s-mode (ppb)
Number who successfully completed at
least one measurement (%)
10 (83.3)
Mean FeNO (standard deviation) 12.6 (13.28)
Median 9.0
Minimum, maximum 5, 49
FeNO 10 s-mode (ppb)
Number who successfully completed at
least one measurement (%)
7 (58.3)
Mean FeNO (SD) 10.6 (4.86)
Median 10.0
Minimum, maximum 5, 19
FeNO fractional exhaled nitric oxide
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reproducible [51–53], providing cost-effective
and real-time inflammatory data [54, 55].
Management to Reduce Exacerbations
Perhaps the most important aspect of
incorporating FeNO in asthma management is
the reduction in the risk of exacerbations. It is
speculated that exacerbations are preceded by
an increase in eosinophilic airway
inflammation, so FeNO levels may identify
patients at risk of exacerbations given the level
of cross-correlation between FeNO and
symptoms [56, 57].
In clinically stable adults with asthma, the
combined use of FeNO and forced expiratory
volume in 1 s (FEV1) positively predicted the
risk of exacerbation (FeNO C28 ppb; FEV1 B76
%) showing an 85 % probability of a future
exacerbation, while those with FeNO levels
\28 ppb and FEV1 [76 % showed no risk of
exacerbation [32, 58]. FeNO may predict loss of
control following ICS withdrawal [32, 59, 60],
and FeNO has been associated with a positive
predictive value of 80–90 % for predicting and
diagnosing loss of control [32, 59]. When FeNO
was used to guide treatment and manage
asthma in pregnant women, there was a
substantial reduction in exacerbations in the
FeNO-managed group compared to the control
group [61].
More recently, three studies have shown that
the use of a handheld NO analyzer can reduce
exacerbations by as much as 50 % [62–64]. In
adults, Syk et al. showed that the use of FeNO to
guide treatment alongside usual clinical care
reduced the frequency that asthma symptoms
worsened [62]. Keeping inflammation under
control can reduce the risk of catching a viral
infection or having that viral infection lead to
an exacerbation. Using FeNO to guide
treatment does not lead to fewer symptom-free
days but does decrease the frequency of asthma
exacerbations [63]. In the study by Peirsman
et al., 24 % of children with asthma who were
monitored by FeNO experienced exacerbations
compared to 48 % from the control group [57],
and Petsky et al. reported a smaller percentage
of children (22 %) experienced exacerbations
when FeNO was utilized to manage their
Fig. 4 Fractional exhaled nitric oxide levels can help
differentiate between asthma phenotypes (Illustration used
with kind permission from Ricciardolo et al. [16])





















asthma, compared to 54 % when it was not [64].
Petsky et al. also showed that taking atopy into
account reduces the number of severe
exacerbations, although higher doses of ICS
were administered. However, they concluded
that FeNO is unlikely to be beneficial for
improving asthma symptoms. This seems to
suggest that symptoms and exacerbations are
not related to the same physiological
mechanisms, with one more strongly related
to airway inflammation and one more strongly
related to bronchoconstriction [64].
High FeNO levels in ICS-treated patients
usually suggest uncontrolled asthma with high
FeNO being correlated with high use of
short-acting beta-agonists and oral
corticosteroids as well as lower predicted FEV1
levels during the preceding year compared to
patients with low FeNO values [65]. In the
follow-up study, high FeNO was shown to
predict future uncontrolled asthma in patients
treated with ICS; by adding FeNO to an asthma
control questionnaire and spirometry during
routine visits, patients likely to suffer
exacerbations could be identified [66].
Negative studies on the use of FeNO for
asthma management have been reported
[32, 67–70]. Use of FeNO was not
recommended to tailor ICS treatment when
compared to managing treatment based on
clinical symptoms alone in a meta-analysis in
2009 [70]. However, this meta-analysis did not
include many of the most recent studies that
demonstrated a decrease in exacerbations, these
studies were small, the majority of subjects had
mild-to-moderate asthma, and the means of
measuring outcomes varied. Indeed, a newer
meta-analysis of these data with the addition of
newer studies showed the rate of exacerbations
to be significantly lower in FeNO-guided
children compared with the control group
[27]. This result was confirmed recently in a
further meta-analysis in children [71].
Combining the results of six eligible studies
involving children, the odds ratio of
exacerbation was significantly lower in the
FeNO-guided management group (OR 0.690,
95 % CI 0.532, 0.895; p = 0.005). Further
research is planned, and a large multicenter
study in the UK is due to start recruitment by
the end of 2016.
Adherence and Objective Goals
with Patients
In clinical practice, I have found that FeNO is a
very useful indicator of adherence. In
particular, unexplained changes in FeNO
measurements within an individual over time
should prompt a more complete review of
medication use. FeNO has the potential to
monitor ICS adherence because FeNO responds
quickly and dose dependently to ICS treatment
[26, 29, 32, 72]—persistently high FeNO levels
may indicate poor compliance [73].
Optimum ICS dosing is important for
ensuring patient safety while maintaining
adequate asthma control [32]. However, in
order to obtain these benefits, ICS must be
taken regularly, and many studies have shown
that treatment compliance among patients with
asthma is frequently poor, which leads to loss of
control and increased morbidity [74]. Reliably
identifying non-compliance could be valuable
in improving the understanding of factors
contributing to on-going symptoms in asthma
[29, 74].
Increased FeNO levels ([25 ppb) in children
prescribed ICS was associated with reduced
treatment adherence (OR 0.25, 95 % CI
0.15–0.41) [32, 75], and improved ICS
adherence correlated with a greater reduction
in FeNO in patients with difficult-to-treat
asthma [29, 32]. Another study found serial
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FeNO measurements helped to determine
treatment adherence and showed that
adherence with ICS was significantly
associated (p\0.001) with a fall in FeNO over
the study period [12, 22]. Although elevated
FeNO levels may reflect poorer adherence,
confounding factors such as disease activity
and inhaler technique need to be carefully
considered [74]. It is not unusual, in my
clinical experience, to see an increase in FeNO
accompanied by a ‘loss of optimal inhaler
technique’ in many children and young
adults. This is often a complete surprise to
parents, particularly when they find that the use
of large-volume spacers has been abandoned or
that other important steps in inhaler use are
being omitted.
Cost-Effectiveness and Recent NICE
Recommendations
FeNO is a useful tool for targeting those patients
who will benefit from anti-inflammatory
treatment [76]. In difficult, poorly controlled
asthma, when symptoms may have multiple
causes, FeNO may be used to monitor treatment
to avoid unnecessary increases in steroid
therapy [76, 77]. This is particularly important
in light of financial constraints in healthcare
especially given the large cost implication of
ineffective treatments. FeNO measurements
offer the potential to reduce costs while
simultaneously improving the quality of
patient care with more accurate phenotypic
assessment and precision treatment [76].
In the US, 30 % of asthma patients have
severe or difficult-to-treat asthma, achieve
suboptimal control and show relative
non-responsiveness to medication. It is
estimated that this relatively small proportion
of patients accounts for 80 % of asthma medical
costs [31]. Adding FeNO to standard asthma
management offers potential cost savings. The
inclusion of FeNO measurements may ensure
parity was reached with the current standard of
care in the US, assuming a reduction of 5 % in
hospitalization and emergency department
costs; this is despite the costs of performing
the FeNO tests [31].
The cost effectiveness of FeNO was
investigated in a German study [30]. Based on
a reimbursement price of €34 using the
portable analyzer, NIOX MINO, an asthma
diagnosis cost €12 more per patient than
standard diagnostic methods, but offered
improved accuracy. The use of FeNO in
treatment decisions was less costly than
standard asthma management and provided
similar health benefits.
In the UK, FeNO is recommended by the
National Institute for Health and Care
Excellence (NICE) as a cost effective
measurement for the diagnosis and
management of asthma when used as an
adjunct to traditional clinical testing [26].
NICE also considers FeNO as a potential tool
for monitoring treatment adherence [26]. NICE
compared the use of three NO analyzers (NIOX
MINO, NIOX VERO and NOBreath) with
current standard tests used in England and
Wales [26]. Base-case results for asthma
management in children and adults indicated
that the use of FeNO alongside tests
recommended by the British guidelines
produced a small health benefit in terms of
disease burden [0.05 quality-adjusted life year
(QALY)] when compared to following the
British guidelines alone (0.04 QALY), although
the addition of FeNO increased costs because of
projected ICS use. Their review also showed that
FeNO testing plus bronchodilator reversibility
testing in adults and children delivered equal or
greater QALYs at a lower incremental
cost-effectiveness ratio (ICER) than other tests
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and that FeNO assessment in conjunction with
existing tests was more cost-effective than when
existing tests were used alone. They concluded
that FeNO was both cost and clinically effective
when used to support symptomatic asthma
management in adults and children using ICS,
with the caveat that the results should be
interpreted with caution given the uncertainty
relating to the economic models used. FeNO is
not recommended to help the stepping down of
ICS use [26].
FUTURE RESEARCH
In the UK, measurement of FeNO has gradually
crept into clinical practice. Initial concerns
about cost and the reliability of the
measurements have been replaced largely with
a growing enthusiasm as clinicians have found
the technology easy to use and helpful in
guiding treatment decisions. This change was
reflected in the recent interim NICE guidance
on diagnosis and management of asthma [26].
Nonetheless, many uncertainties exist, and
there are still large gaps in the evidence base,
particularly in children.
Pre-School Wheeze and FeNO
As I reflect upon clinical practice in wheezing
pre-school children, I am reminded of the
aphorism popularized by Maslow: ‘If all you
have is a hammer then everything looks like a
nail’ [78]. Thus, for clinicians there is a
temptation to label everything that wheezes as
asthma as treatments are both available and of
proven efficacy. Pre-school wheeze is a common
problem, affecting up to a third of all children
[79, 80]. The disappointing results from recent
randomized controlled studies in this group of
children have highlighted the lack of evidence
for any effective treatments in an unrefined
population of early-onset wheezers [81, 82].
There is an urgent need for improved
identification of endotypes in young wheezy
children, particularly those who present acutely
and recurrently to hospital with viral-induced
wheeze.
Current treatment strategies broadly separate
children into two distinct groups: those with
episodic viral symptoms or those with multiple
triggers [79, 80]. In clinical practice, intuition
and experience are required as parental report
alone is often misleading [83]. Despite a paucity
of evidence, children with recurrent symptoms
are often treated speculatively with either
increasing doses of ICS or LTRA. FeNO
discriminates between different subtypes of
wheeze and predicts the likely natural history
[84, 85]. Studies are now required to determine
whether FeNO plus clinical parameters can be
used to predict response (or non-response) to
any treatment.
Longitudinal Measurement of FeNO
and Home Measurement
Studies in which longitudinal measures of FeNO
have been used to drive clinical decisions have
not been wholly successful in either adults or
children [32]. This is probably due to a number
of factors including differences in study design,
sample size, methodology, the application of
different FeNO algorithms and devices, and
inconsistencies in predefined study endpoints.
The desire to define a single value upon which
treatment decisions are based is almost certainly
a big limitation and works contrary to
everything that is known about personalized
medicine.
The (lack of) evidence here seems at odds
with what is known about the biology and
clinical experience. In clinical practice, a
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change in FeNO (in either direction) in an
individual patient can give important clues
about adherence (intentional or
non-intentional) and even predict a likely
moderate exacerbation in advance of other
symptoms [57]. Daily measurement of FeNO is
not practical for most clinical care and would
only be possible if home monitoring was
available. Home use of spirometry to enhance
clinical management in children has been
disappointing, largely because effort
diminishes in most individuals over time
[86, 87]. However, FeNO measurement is less
effort dependent and may allow rational
treatment adjustments to be made between
clinic appointments in response to variation in
airway inflammation.
CONCLUSION
Throughout the last decade we have appeared
to be on the threshold of an era of personalized
medicine for asthma. Despite the regular
headlines and breakthrough discoveries, this
has mostly failed to emerge and make its way
into clinical practice. However, a change of
approach moving away from classic
phenotyping and the identification of
biologically relevant endotypes is already
bearing fruit. The measurement of FeNO is
helpful in securing an accurate diagnosis, and
data are emerging showing that FeNO-guided
management is likely to reduce the risk of
exacerbation. The NIOX VERO device builds
upon existing sensor technologies to provide
accurate, easy, point-of-care measurement of
FeNO. Its clear, user-friendly display and
portability represent significant improvements
over preceding devices while matching their
accuracy and precision.
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